Fortress Biotech(FBIO) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights Fortress' late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 Miami, FL – May 15, 2024 – Fortress Biotech, Inc. (Nasdaq: ...